Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. Why did this happen? For more information you can review our Terms of Service and Cookie Policy. Mavacamten is being developed to treat obstructive and non-obstructive forms of a condition called hypertrophic cardiomyopathy - estimated to affect one in every 500 people globally. Mavacamten is being developed to treat obstructive and non-obstructive forms of a condition called hypertrophic cardiomyopathy - estimated to affect one in every 500 people globally.
hypertrophic cardiomyopathy is easy to treat.
( z0 easy :ARG1 ( z1 treat :ARG2 ( z2 disease :name ( z3 name :op "hypertrophic" :op "cardiomyopathy" ) ) ) )
(z0 / easy-05
    :ARG1 (z1 / treat-03
              :ARG2 (z2 / disease
                        :name (z3 / name
                                  :op1 "hypertrophic"
                                  :op2 "cardiomyopathy"))))
hypertrophic cardiomyopathy is easy to treat .
z2 :name z3
z3 :op1 1
z3 :op2 0
z0 :ARG1 z1
z1 :ARG2 z2